The Pyelonephritis Treatment Market is expected to reach at a CAGR of 5.8% during the forecast period 2025-2033. The Pyelonephritis Treatment Market is driven by rising UTI cases, advanced antibiotics ...

The Food and Drug Administration (FDA) has granted Qualified Disease Product and Fast Track designation to NRX-101 for the treatment of complicated urinary tract infection (cUTI) and pyelonephritis.

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation ...

intravenous antibiotics Cefepime-enmetazobactam may be more effective than piperacillin-tazobactam in treating complicated UTI and acute pyelonephritis caused by organisms that produce ...

Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...

"The five factors with the highest odds of developing APN included obstructive and reflux uropathy, presentation to an acute care facility, urinary retention, history of UTI, and renal comorbidities.

Urinary tract infections (UTIs) can cause back pain, especially if the infection spreads to the kidneys, leading to pyelonephritis. Recognizing sympto ...

Researchers from Shaanxi Panlong Pharmaceutical Group Co. Ltd., Shaanxi Pioneer Biotech Co. Ltd. and affiliated organizations presented the discovery and preclinical characterization of novel ...